CXCL8 and non-small cell lung carcinoma: Finally, in a study of 143 stage IIIB/IV NSCLC patients treated with anti-PD-(L)1 alone or in combination with chemotherapy, higher IL-8 levels were detected at baseline in non-responders than responders (p < 0.05) [31].